賽里斯治療 MCRB 深 滬
等待開盤 03-26 09:30:00 美东时间
9.14
+0.860
+10.39%
華盛通- 最 高9.50
- 今 開8.48
- 成交量 4.61万股
- 最 低 8.3813
- 昨 收 8.28
- 總市值 8268.52万
- 52周最高 29.98
- 市盈率 靜 14.23
- 換手率 0.51%
- 52周最低 6.53
- 委 比 -99.29%
- 總股本 904.65万
- 歷史最高 1040.00
- 量 比 0.81
- 振 幅 13.51%
- 歷史最低 7.20
- 每 手 1
- 風險率 4.28%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Seres Therapeutics posts 2025 profit as expenses fall
Seres Therapeutics posts 2025 profit as expenses fall Overview US biotechnology firm's 2025 net income from continuing ops was $5.7 mln, reversing prior loss 2025 revenue was $789,000 as company focused on early-stage pipeline and transition services Seres cut R&D and G&A expenses yr/yr as it priori
03-12 19:14
Earnings Scheduled For March 12, 2026
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is likel...
03-12 19:11
Seres Therapeutics Q4 EPS $(1.76) Beats $(2.22) Estimate, Sales $438.000K Miss $5.875M Estimate
Seres Therapeutics (NASDAQ:MCRB) reported quarterly losses of $(1.76) per share which beat the analyst consensus estimate of $(2.22) by 20.61 percent. This is a 10 percent decrease over losses of $(1.60) per share from
03-12 19:10
BRIEF-Seres Therapeutics FY EPS USD 0.64
BRIEF-Seres Therapeutics FY EPS USD 0.64 Mar 12 (Reuters) - Seres Therapeutics FY collaboration revenue USD 789 thousand. FY operating expenses USD 94.76 million FY net income USD 5.696 million FY operating income USD -93.971 million
03-12 19:00
Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Seres Therapeutics reported 2025 financial results, with a net income of $5.7 million from continuing operations, compared to a net loss of $125.8 million in 2024. The company is advancing Ser-155 for immune checkpoint-related enterocolitis and allo-HSCT, with Q2 2026 data readouts expected. Ser-603 for IBD is in preclinical stages. The company has $45.8 million in cash, expecting to fund operations through Q3 2026.
03-12 11:00
Seres Therapeutics Announces Executive Leadership Changes and Promotions
An update from Seres Therapeutics ( ($MCRB) ) is now available. On February 27,...
03-03 05:55
Seres Therapeutics Appoints Richard N. Kender As Executive Chair And Interim CEO
Seres Therapeutics, Inc. (NASDAQ:MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced the appointment of Richard N. Kender as Executive Chair and Interim Chief Executive Officer. Mr.
03-03 05:13
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates
Seres Therapeutics has appointed Richard N. Kender as Executive Chair and Interim CEO, bringing over 35 years of biopharma experience. The company is advancing its live biotherapeutic programs, including SER-155 for immune checkpoint-related enterocolitis, with clinical data expected in Q2 2026. SER-155 is also Phase 2 ready for patients undergoing allogeneic hematopoietic stem cell transplant. The company continues to pursue funding and strategi...
03-02 21:05
Seres Therapeutics Finalizes Protocol For Phase 2 Study Of SER-155 In Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant With FDA
Seres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the FDA and has advanced key study startup activities and will pause
02-12 20:20
